Fiduciary Alliance LLC Has $3.08 Million Stock Position in Abbott Laboratories (NYSE:ABT)

Fiduciary Alliance LLC lifted its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 29.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 23,206 shares of the healthcare product maker's stock after purchasing an additional 5,270 shares during the period. Fiduciary Alliance LLC's holdings in Abbott Laboratories were worth $3,078,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in ABT. Redwood Park Advisors LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $25,000. Noble Wealth Management PBC acquired a new stake in Abbott Laboratories in the 4th quarter worth $26,000. NewSquare Capital LLC increased its holdings in shares of Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock worth $27,000 after purchasing an additional 105 shares during the period. WealthTrak Capital Management LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter valued at about $28,000. Finally, Rialto Wealth Management LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $29,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Insider Transactions at Abbott Laboratories

In related news, EVP Lisa D. Earnhardt sold 91,167 shares of Abbott Laboratories stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $133.82, for a total value of $12,199,967.94. Following the completion of the sale, the executive vice president now directly owns 71,928 shares in the company, valued at $9,625,404.96. This trade represents a 55.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sally E. Blount sold 2,600 shares of the company's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total transaction of $337,116.00. Following the transaction, the director now owns 34,058 shares in the company, valued at approximately $4,415,960.28. The trade was a 7.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock traded up $0.17 during mid-day trading on Tuesday, reaching $133.74. 5,914,174 shares of the stock were exchanged, compared to its average volume of 6,150,016. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $141.23. The company has a market cap of $232.69 billion, a price-to-earnings ratio of 17.48, a price-to-earnings-growth ratio of 2.52 and a beta of 0.74. The firm has a 50-day simple moving average of $130.60 and a 200 day simple moving average of $125.43. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.02. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.38 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. On average, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Analyst Ratings Changes

ABT has been the topic of several research reports. Wall Street Zen lowered Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, February 12th. Royal Bank of Canada lifted their price objective on Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a report on Thursday, April 17th. Barclays upped their target price on Abbott Laboratories from $158.00 to $159.00 and gave the company an "overweight" rating in a research note on Thursday, April 17th. Jefferies Financial Group lifted their price target on shares of Abbott Laboratories from $135.00 to $137.00 and gave the stock a "hold" rating in a research note on Thursday, April 17th. Finally, Citigroup boosted their price target on shares of Abbott Laboratories from $135.00 to $160.00 and gave the company a "buy" rating in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Abbott Laboratories has an average rating of "Moderate Buy" and an average target price of $142.59.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.